VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
MedTech & Diagnostics

Labcorp Holdings Executive Compensation (FY25)

LH · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Adam Schechter
Latest say-on-pay support
=
May 26, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing

The Labcorp Holdings brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
Get the executive briefGet the board briefNo account needed.
Data as of November 3, 2026Latest filing (8-K): May 26, 2026
12 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Labcorp Holdings brief$500Get the executive brief
Velarion Intel, one year, every company
354 figures on this page: 346 cited to the filing that reported them, 8 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Adam Schechter: $19,327,354 → $18,339,913 (5.1% lower)
Say-on-pay support: 91.9% → 94.7% (2.8 points higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Labcorp Holdings' chief executive and what were they paid?
Adam Schechter was paid $18,339,913 in total compensation as President and Chief Executive Officer for fiscal 2025. Schechter's total moved 5.1% lower from the $19,327,354 reported for fiscal 2024.
What was Labcorp Holdings' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 94.7% of votes cast for or against in favor at the meeting held May 26, 2026.
Which companies are in Labcorp Holdings' peer group?
Companies named in the disclosed peer group include Agilent Technologies, Inc., Baxter International Inc., Becton, Dickinson and Company Incorporated, Boston Scientific Corporation and Charles River Laboratories, among others.
What is Labcorp Holdings' chief executive pay ratio?
The company reported a chief executive pay ratio of 292:1 for fiscal 2025, against median employee compensation of $62,929.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Adam Schechter
President and Chief Executive Officer
◇—◇◇◇—◇◇
GLENN Eisenberg
Executive Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
PAUL Kirchgraber
Executive Vice President and Chief Executive Officer, Early Development, Central Laboratories and Oncology
◇—◇◇◇—◇◇
Brian Caveney
Executive Vice President and President, Early Development and Chief Medical and Scientific Officer
◇—◇◇◇—◇◇
MARK Schroeder
Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Adam Schechter
President and Chief Executive Officer
◇—◇◇◇—◇◇
PAUL Kirchgraber
Executive Vice President and Chief Executive Officer, Early Development, Central Laboratories and Oncology
◇—◇◇——◇◇
GLENN Eisenberg
Executive Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
THOMAS Pike
Executive Vice President
◇—◇———◇◇
MARK Schroeder
Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer
◇—◇◇◇◇◇◇
Brian Caveney
Executive Vice President and President, Early Development and Chief Medical and Scientific Officer
◇—◇◇◇—◇◇
Anita Graham
Executive Vice President and Chief Human Resources Officer
◇◇◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Adam Schechter
President and Chief Executive Officer
◇—◇◇◇—◇◇
Glenn Eisenberg
Executive Vice President and Former Chief Financial Officer
◇—◇◇◇—◇◇
Mark Schroeder
Former Executive Vice President and President, Diagnostics and Chief Operations Officer
◇—◇◇◇◇◇◇
Brian Caveney
Executive Vice President and President, Early Development Research Laboratories and Chief Medical and Scientific Officer
◇—◇◇◇—◇◇
Julia Wang
Executive Vice President and Chief Financial Officer
◇—◇◇——◇◇
Anita Graham
Executive Vice President and Chief Human Resources Officer
◇◇◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Adam Schechter
President and Chief Executive Officer
◇—◇◇◇—◇◇
Julia Wang
Executive Vice President and Chief Financial Officer
◇◇◇◇◇—◇◇
Mark Schroeder
Former Executive Vice President and President, Diagnostics and Chief Operations Officer
Departed during or after this year
◇—◇◇◇◇◇◇
Brian Caveney
Executive Vice President and President, Early Development Research Laboratories and Chief Medical and Scientific Officer
◇—◇◇◇—◇◇
Megan Bailey
Executive Vice President and President, Central Laboratories and International
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Adam SchechterRSU◇——◇——◇
Adam SchechterPSU◇◇◇—◇—◇
Adam SchechterOPTION◇——◇—◇◇
Brian CaveneyRSU◇——◇——◇
Brian CaveneyPSU◇◇◇—◇—◇
Brian CaveneyOPTION◇——◇—◇◇
Julia WangOPTION◇——◇—◇◇
Julia WangRSU◇——◇——◇
Julia WangPSU◇◇◇—◇—◇
Mark SchroederPSU◇◇◇—◇—◇
Mark SchroederOPTION◇——◇—◇◇
Mark SchroederRSU◇——◇——◇
Megan BaileyOPTION◇——◇—◇◇
Megan BaileyPSU◇◇◇—◇—◇
Megan BaileyRSU◇——◇——◇
Fiscal 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Adam SchechterRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Julia WangRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Megan BaileyRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Brian CaveneyRSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Adam Schechter
President and Chief Executive Officer · Severance agreement
Severance multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Excise tax treatment◇
Non-compete period◇
Non-solicit period◇
Clawback◇
Brian Caveney
Executive Vice President and President, Early Development Research Laboratories and Chief Medical and Scientific Officer · Severance agreement
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Non-solicit period◇
Clawback◇
Julia Wang
Executive Vice President and Chief Financial Officer · Severance agreement
Severance multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Excise tax treatment◇
Non-compete period◇
Non-solicit period◇
Clawback◇
Mark Schroeder
Former Executive Vice President and President, Diagnostics and Chief Operations Officer · Severance agreement
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Non-solicit period◇
Clawback◇
Megan Bailey
Executive Vice President and President, Central Laboratories and International · Severance agreement
Severance multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Non-solicit period◇
Clawback◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Garheng Kong
Lead independent director
◇◇———◇◇
Jeffrey A. Davis
◇◇———◇◇
Richelle P. Parham
◇◇———◇◇
Paul B. Rothman
◇◇———◇◇
Peter M. Neupert
◇◇———◇◇
Kerrii B. Anderson
◇◇———◇◇
D. Gary Gilliland
◇◇———◇◇
Kathryn E. Wengel
◇◇———◇◇
Kirsten M. Kliphouse
◇◇———◇◇
Victor Bulto
◇◇———◇◇
John H. Sampson and Adam H. Schechter served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Lead independent director premium◇
Audit committee chair◇
Compensation committee chair◇
Nominating and governance chair◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Agilent Technologies, Inc. A
  • Baxter International Inc. BAX
  • Becton, Dickinson and Company Incorporated BDX
  • Boston Scientific Corporation BSX
  • Charles River Laboratories CRL
  • Henry Schein, Inc. HSIC
  • Hologic, Inc. HOLX
  • Quest Diagnostics Incorporated DGX
  • Stryker Corporation SYK
  • Tenet Healthcare Corporation THC
  • Universal Health Services UHS
  • Viatris VTRS
  • Zimmer Biomet Holdings, Inc. ZBH

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 26, 2026=◇◇◇
2024May 20, 2025=◇◇◇
2023May 14, 2024=◇◇◇
2022May 11, 2023=◇◇◇
2021May 11, 2022=◇◇◇
2020May 12, 2021=◇◇◇
2019May 13, 2020=◇◇◇
2018May 9, 2019=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Adam Schechter (President and Chief Executive Officer), FY2025 total compensation $18,339,913 (base salary $1,435,000) [exec_comp, SEC accession 0001193125-26-150752, filed 2026-04-10]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Labcorp Holdings files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Labcorp Holdings disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Labcorp Holdings sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Labcorp Holdings' disclosed peer group is defensible, who names Labcorp Holdings back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
354 figures on this page: 346 cited to the filing that reported them, 8 calculated from figures it prints.
346 cited to the filing
8 calculated from the filing

Documents cited

  1. 0000920148-26-000143
  2. 0001193125-26-150752
    CEO Pay Ratio · DIRECTOR COMPENSATION · Outstanding Equity Awards at Fiscal Year-End · Summary Compensation Table
  3. 0000920148-25-000069
  4. 0001193125-25-072853
    Summary Compensation Table
  5. 0000920148-24-000036
  6. 0001193125-24-087342
    Summary Compensation Table
  7. Employment Agreement
  8. 0000920148-23-000038
  9. 0001193125-22-150330
  10. 0001193125-21-162006
  11. 0001193125-20-145193
  12. 0001193125-19-145334
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Labcorp Holdings executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/LH (accessed 2026).
Short form: data: Velarion

The Labcorp Holdings brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
Get the executive briefGet the board briefNo account needed.
12 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Labcorp Holdings and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

MedTech & Diagnostics rankings

Chief executive pay — MedTech & DiagnosticsCEO pay ratio — MedTech & DiagnosticsSay-on-pay support — MedTech & Diagnostics

Peers Labcorp Holdings discloses

The companies named in LH's own disclosed peer group.

Agilent Technologies, Inc.Baxter International Inc.Becton, Dickinson and Company IncorporatedBoston Scientific CorporationCharles River LaboratoriesHenry Schein, Inc.Hologic, Inc.Quest Diagnostics IncorporatedStryker CorporationTenet Healthcare CorporationUniversal Health ServicesViatrisZimmer Biomet Holdings, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy